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Summary
The efficient spread of malaria from infected humans to mosquitoes is a major chal-
lenge for malaria elimination initiatives. Gametocytes are the only Plasmodium life 
stage infectious to mosquitoes. Here, we summarize evidence for naturally acquired 
anti-gametocyte immunity and the current state of transmission blocking vaccines 
(TBV). Although gametocytes are intra-erythrocytic when present in infected hu-
mans, developing Plasmodium falciparum gametocytes may express proteins on the 
surface of red blood cells that elicit immune responses in naturally exposed individu-
als. This immune response may reduce the burden of circulating gametocytes. For both 
P. falciparum and Plasmodium vivax, there is a solid evidence that antibodies against 
antigens present on the gametocyte surface, when co-ingested with gametocytes, 
can influence transmission to mosquitoes. Transmission reducing immunity, reducing 
the burden of infection in mosquitoes, is a well-acknowledged but poorly quantified 
phenomenon that forms the basis for the development of TBV. Transmission enhanc-
ing immunity, increasing the likelihood or intensity of transmission to mosquitoes, is 
more speculative in nature but is convincingly demonstrated for P. vivax. With the 
increased interest in malaria elimination, TBV and monoclonal antibodies have moved 
to the center stage of malaria vaccine development. Methodologies to prioritize and 
evaluate products are urgently needed.
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1  | INTRODUC TION
Malaria is one of the few infectious diseases earmarked for world-
wide eradication by the World Health Organization (WHO).1,2 The 
majority of the malaria cases are caused by infection with Plasmodium 
falciparum or Plasmodium vivax. While P. falciparum is the dominant 
Plasmodium species in most of Africa and is associated with the most 
severe morbidity and mortality, P. vivax is more widely distributed 
and is increasingly recognized as an important source of morbidity 
and restrained economic productivity.3 Malaria control efforts in the 
recent decades, including improved access to efficacious treatment 
and vector control, were followed by significant reductions in malaria 
burden4 and stimulated malaria elimination initiatives. Despite these 
successes, the WHO estimates that there were 219 million new ma-
laria cases and 435 000 malaria-related deaths in 2017.5 This figure 
has remained fairly stable since 2015 indicating that progress has pla-
teaued; some countries even experience recent increases in malaria 
burden and several more are off track in their elimination efforts.5 
The emergence of parasite resistance to antimalarials6,7 and mosquito 
resistance to insecticides8 are important threats to recent gains. One 
of the major challenges for malaria elimination initiatives is the very 
efficient spread of malaria from infected humans to mosquitoes.1 
Interventions that target this process and interrupt transmission to 
mosquitoes may be crucial to achieve elimination in many areas.9
Gametocytes are the only Plasmodium life stages that are in-
fectious to mosquitoes, so the uptake of these specialized forms 
by blood-feeding female Anopheles mosquitoes is essential for hu-
man-to-mosquito transmission. Plasmodium falciparum gametocytes 
form when asexual schizonts become committed to produce sexual 
progeny by the activation and expression of the Apatella2-g gene 
(AP2-G).10,11 The expression of AP2-G is under tight epigenetic con-
trol by P. falciparum heterochromatin protein 1 (PfHP1).12 The inter-
play between histone deacetylases13 and gametocyte development 
1 (GDV1)14 in turn determines the binding or release of PfHP1 and 
thus the expression of AP2-G. AP2-G is a highly conserved member 
of the apicomplexan AP2 (APiAP2) family of DNA binding proteins 
whereby its DNA binding domains are highly conserved across all 
Plasmodium species; all P. falciparum ApiAP2 proteins have syntenic 
homologues in P. vivax and are expressed at a similar stage of de-
velopment.15 For P. falciparum, gametocyte formation is a 10-12 day 
process during which the parasite passes through five morpholog-
ically distinct forms (stages I-V) (Figure 1). Immature gametocytes 
(stages I-IV) sequester outside the peripheral circulation, primarily 
in the bone marrow and spleen,16 and are released in the circula-
tion to complete their final maturation steps.17 The mature stage 
V gametocytes then become accessible in the peripheral blood for 
uptake by blood-feeding mosquitoes.18 The development of P. vivax 
gametocytes is markedly faster than P. falciparum and only approxi-
mately 48 hours are required for maturation19 that may also involve 
a bone marrow phase.20 The circulation time of P. falciparum and P. 
vivax gametocytes differs significantly. While mature P. falciparum 
gametocytes can be detected for several weeks after clearance of 
asexual parasites,21,22 the half-life of P. vivax gametocyte is very 
short,23 with microscopically detectable gametocytes and gameto-
cyte-specific mRNA disappearing within days of asexual stage clear-
ance.23,24 Stage V P. falciparum gametocytes can be morphologically 
recognized by their characteristic crescent shape, while mature P. 
vivax gametocytes display a round shape and almost fill the entire 
red blood cell (RBC)19 (Figure 1).
In the mosquito midgut, Plasmodium gametocytes rapidly egress 
from the host erythrocyte and develop into gametes. Gametogenesis 
is induced by a reduction in temperature, increase in pH and expo-
sure to xanthurenic acid.25,26 Male gametocytes exflagellate produc-
ing up to eight motile microgametes; whereas, female gametocytes 
“round-up” to form one immotile macrogamete.27,28 Fertilization of a 
macrogamete by a microgamete results in the formation of a zygote, 
which then develops into an intermediate “retort” leading to the for-
mation of a mature motile ookinete that traverses the midgut wall 
and forms an oocyst. Approximately 10-12 days after blood meal 
ingestion the rupture of oocysts results in the release of sporozoites, 
which will invade the mosquito salivary glands completing the mos-
quito stage of the Plasmodium life cycle.29
Many factors influence the likelihood of gametocytes being 
transmitted to mosquitoes and establishing a successful mosquito 
stage infection.30 Considerably more work on gametocyte biol-
ogy and infectivity has been performed for P. falciparum than for 
P. vivax, although it is likely that many factors are shared between 
Plasmodium species. General parasite characteristics that have been 
associated with differences in transmission potential and infectivity 
include gametocyte density31-34 (Figure 2), concurrent asexual para-
site density,35,36 ratio of male and female gametocytes,31,37 duration 
of infection,35,38 and level of gametocyte maturity.39 Host factors 
such as anemia, age, mosquito factors, and importantly, human im-
munity are also known to affect gametocyte infectiousness.40,41
The first empirical evidence that human immune responses to ga-
metocytes could affect their infectiousness to mosquitoes came from 
immunization studies in birds,42-44 following earlier observations that 
gametocyte infectivity per capita appeared to change the course of 
an infection.45,46 These experiments led to the identification of a small 
number of proteins expressed by gametocytes, gametes or ookine-
tes, which for decades have been the focus of gametocyte research 
and formed the basis of malaria transmission blocking vaccine (TBV) 
development.47,48 Research on gametocyte immunobiology has been 
outweighed by research on the life stages leading to human infection 
(the pre-erythrocytic stages) and clinical disease (the asexual blood 
stages), but as TBV development has gained pace our understanding 
of gametocyte biology has improved dramatically. In 2002, the P. fal-
ciparum genome49 and proteome50,51 were first published. These and 
many subsequent investigations have revealed biology that is unique 
to gametocytes (reviewed by Beri et al52), the gametocyte sexes,53,54 
and different stages of their development.55 An integrated approach 
using proteomic and transcriptomic data from 18 studies predicted 602 
proteins to be enriched in P. falciparum gametocytes56; transcriptome 
analysis in P. vivax revealed that the expression of 1613 genes was cor-
related with the expression of known gametocyte genes.57 Many of the 
proteins produced specifically by gametocytes remodel the human host 
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cell to support their morphological development,58 while others have 
roles during gametogenesis and fertilization in the mosquito. These pro-
teins represent potential targets of gametocyte-specific immunity.
This review will discuss the evidence for the existence of naturally 
acquired human immune responses against the sexual parasite stages 
of P. falciparum and P. vivax, discuss the effect of these responses on 
transmission, and propose strategies for transmission blocking inter-
ventions. Immature and mature gametocytes have markedly different 
biology, morphology, and preferential localization in human tissues. 
Immune responses to early and late gametocytes therefore have the 
potential to affect transmission differently; early gametocyte immu-
nity could reduce the number of gametocytes achieving maturity in 
the peripheral blood, while late gametocyte immunity may affect ga-
metocyte number and their likelihood of undergoing successful spo-
rogonic development in the mosquito. While this review will focus on 
P. falciparum, we will also summarize the current state of knowledge 
for the less-studied P. vivax and indicate major knowledge gaps with 
regard to anti-gametocyte immunity, implications for transmission 
dynamics and potential vaccine strategies.
Merozoites that are released from infected liver cells invade 
RBCs to initiate the erythrocytic cycle. The sexual development is 
initiated by a subset of parasites that are committed to produce ga-
metocytes. Immature P. falciparum gametocytes sequester outside 
the peripheral circulation, primarily in the bone marrow and spleen. 
Their maturation (10-12 days) involves five distinct developmental 
stages (I-V); mature stage V are released in the peripheral circula-
tion. Plasmodium vivax gametocytogenesis may also involve a blood 
marrow phase, but in contrast to P. falciparum only takes 48 hours. 
After ingestion by a blood-feeding Anopheles mosquito, gameto-
cytes rapidly egress from the host RBC and develop into gametes. 
Male gametocytes exflagellate to form eight microgametes that 
subsequently fertilize a “round-up” microgamete to form a zygote 
leading to the formation of a motile ookinete. The ookinete pene-
trates the midgut wall and forms an oocyst that produces hundreds 
to thousands of sporozoites. Upon oocyst rupture, sporozoites are 
released and migrate to the salivary glands from where they can be 
transmitted to a new human host. Boxes represent surface antigens 
that are under consideration for vaccine development.
2  | IMMUNE RESPONSES AFFEC TING 
GAMETOCY TES IN HUMAN CIRCUL ATION
2.1 | Immune responses targeting gametocyte 
sequestration
Both the asexual and sexual intra-erythrocytic forms of P. falcipa-
rum sequester to avoid prolonged circulation in the blood. Asexual 
F I G U R E  1   The sexual stage development of Plasmodium falciparum and P. vivax parasites. Schematic illustration of the development of 
intra-erythrocytic gametocytes and post-transmission development in the mosquito midgut
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parasites sequester in the tissue microvasculature through well-
defined ligand-receptor interactions; Knob-associated histidine 
rich protein (KAHRP) is critical to the formation of “knobs” on the 
infected erythrocyte surface,59 while members of the P. falciparum 
erythrocyte membrane protein 1 (PfEMP1) family accumulate on 
these knobs and mediate cytoadherence.60 The first stages of P. fal-
ciparum gametocyte development are marked by changes in gene 
expression. Plasmodium falciparum gametocyte exported protein 5 
(PfGEXP5) is detectable 14 hours after RBC invasion by a sexually 
committed merozoite61; Pfs1662 and Pfg2763 are detectable from 
24 to 30 hours post invasion. At the same time, proteins associated 
with asexual stage cytoadherence are down regulated; stage I game-
tocytes still have a smooth surface without any knobs.64 By stage 
II, gametocytes are morphologically distinguishable from asexual 
trophozoites, KAHRP protein is undetectable, and PfEMP1 protein 
is present only at low levels.64 Unlike the asexual blood stages, P. 
falciparum gametocytes sequester primarily in the bone marrow and 
spleen.16,17,65,66 The role of PfEMP1 in early gametocyte infected 
RBC (giRBC) adhesion to the bone marrow vasculature is unclear. 
Adherence of giRBC to either C32 melanoma cells or human bone 
marrow endothelial cells has been demonstrated,67,68 but a later 
study did not detect any adherence of gametocyte stages later than 
F I G U R E  2   Parasite and gametocyte densities in relation to each other and the proportion of infected mosquitoes. Log10 transformed 
parasite (X-axes) and gametocyte (Y-axes) quantities are indicated for Plasmodium falciparum (A) and P. vivax (B). Total parasite density is 
measured using 18S based quantitative polymerase chain reaction (qPCR) and female gametocytes were quantified in reverse transcription-
based qPCR assays that targeted Pfs25 for P. falciparum and Pvs25 for P. vivax. Indicated are parasite and gametocyte densities/µL for P. 
falciparum and gene copies/µL for P. vivax. Parasite and gametocyte culture of NF54 was used for quantification for P. falciparum. For P. 
vivax gene copies were quantified from recombinant plasmids containing the respective genes. Log10 transformed P. falciparum gametocyte 
density/µL (C) and P. vivax transcript copies/µL (D) are indicated in the X-axes with respect to the percent of infected mosquitoes (Y-axes). 
Data points are indicated in filled circles for P. falciparum and unfilled circles for P. vivax
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I and IIa to C32 cells,69 and Silvestrini et al70 demonstrated only lim-
ited adhesion to a variety of endothelial cells. Recently, adhesion 
experiments using bone marrow mesenchymal stromal cells demon-
strated that immature gametocytes were able to adhere to this cell 
type via unknown ligands on the giRBC surface.71
A study using intravital imaging of P. berghei parasites in mice 
demonstrated direct evidence of homing by merozoites to the extra-
vascular niche of the bone marrow and spleen. Using specific inhib-
itors, de Niz et al demonstrated that this extravasation (movement 
from the bone marrow/spleen vasculature to the organ's extravas-
cular space) is mediated via a receptor-ligand interaction72; block-
ing of P-selectin alone reduced the accumulation of gametocytes in 
the bone marrow by 60%. They also provide evidence for invasion 
of RBC precursor cells in the bone marrow by sexual merozoites. 
Several theories have been proposed to explain the enrichment of 
gametocytes in the extravascular space of the bone marrow; eg sex-
ually committed merozoites translocate and gametocytes develop 
in that space, non-sexually committed merozoites translocate there 
and commitment occurs in the extravascular space, or young ga-
metocytes translocate there directly.73 The P. berghei study supports 
the hypothesis that a subset of sexual merozoites bearing specific 
surface ligands home to the bone marrow and spleen, bind the epi-
thelium, move into the extravascular space, and invade erythrocyte 
precursors (abundant in this niche) to become young gametocytes.72 
Comparative experiments in the same study using human autopsy 
material indicate that there is a similar phenomenon possible for P. 
falciparum. These data provide evidence for the presence of surface 
molecules on sexually committed merozoites (or schizonts contain-
ing merozoites) that are involved in cytoadhesion during the process 
of homing and retention in the bone marrow. During the acute phase 
of infection, both asexual and sexual infected erythrocytes accu-
mulate in the bone marrow, suggesting that early gametocytes can 
form in the peripheral blood and may specifically home to the bone 
marrow/spleen. The targeting of any parasite ligands that mediate 
gametocyte sequestration by immune factors could possibly inhibit 
transmission potential.
Numerous studies have shown that immature giRBCs are rigid 
and that a change in host cell deformability occurs in the transition 
to maturity.58,74 Interestingly, the study by de Niz et al showed that 
mature P. berghei gametocytes pass freely into and out of the vascular 
spaces of the bone marrow, and that a switch in host cell deformabil-
ity (here tested by blocking the signal cascade leading to host cell de-
formability) underlies this freedom of movement.72 This supports the 
hypothesis that gametocyte sequestration is maintained not by re-
ceptor-ligand interactions, but by mechanical retention. Additionally, 
the flexibility of mature gametocytes allows them to transit the 
splenic endothelial slits and thereby escape clearance. Members 
of the STEVOR protein family are associated with the erythrocyte 
membrane of immature gametocytes. Accompanying the shift in de-
formability as gametocytes mature STEVOR disappears, indicating a 
possible role for this protein family in this process.58
Naturally induced antibodies may affect gametocyte morphol-
ogy and fitness. In one study, serum antibodies from Thai malaria 
patients were incubated with stage I gametocytes, and were ob-
served to reduce their numbers, interfere with maturation, distort 
their morphology and reduce the number of oocysts developing in 
subsequent mosquito feeding assays.75 Here, the binding of anti-
bodies to the surface of immature forms from stage II onwards was 
described as a possible mechanism for the observed transmission re-
duction. Immune responses against antigens on the immature giRBC 
could affect gametocyte development or circulation time by inter-
fering with sequestration or mediating direct clearance. An epidemi-
ological study performed in Indonesia in the early 1990s compared 
two groups living in an hyperendemic area; native residents and 
transmigrants with no (or limited) history of malaria. Lower gameto-
cyte densities in native residents were attributed to specific immune 
responses,76 giving rise to the hypothesis that naturally acquired 
antibodies against surface antigens on giRBC may directly affect ga-
metocyte densities in circulation independent of a reduction in the 
asexual parasite biomass.
Several studies have aimed to identify the erythrocyte surface 
antigens of immature gametocytes that could be involved in seques-
tration. The first study used a flow cytometry-based method with 
purified P. falciparum 3D7 gametocytes, and observed reactivity of 
immune sera from Gambian children with the surface of mature giR-
BCs, but not with immature stages.77 No association was observed 
in antibody recognition of asexual parasites and mature gameto-
cytes, indicating that a distinct antigen panel is displayed on giRBCs. 
Follow-up data on gametocytemia also suggested that antibodies 
against giRBCs might be able to control gametocyte densities. A 
more thorough study over a 5-week period in a Ghanaian cohort 
also demonstrated the presence of antibodies against mature 3D7 
giRBCs using flow cytometry.78 These findings were confirmed by 
repeating the experiments using two clinical Kenyan isolates. In an-
tibody staining experiments analyzed using microscopy, no antibody 
reactivity was observed against immature giRBCs.
Chan et al quantified antibody reactivity to erythrocytes in-
fected with gametocytes and asexual stages using microscopy 
in order to better understand the difference in humoral response 
against these two life stages.79 Among two Kenyan cohorts, low 
antibody reactivity was observed against stage II to V giRBCs from 
the 3D7 strain. This low reactivity is contrasted with high antibody 
responses to the surface of trophozoite infected erythrocytes. To 
confirm their hypothesis that these high responses are the result of 
reactivity to PfEMP1 the experiment was repeated with two trans-
genic parasite strains with repressed PfEMP1 expression. In the ab-
sence of PfEMP1, surface reactivity of erythrocytes infected with 
asexual parasites was equal to giRBCs, indicating that PfEMP1 is the 
major asexual stage erythrocyte surface antigen. The low levels of 
PfEMP1 expression and the absence of other immunogenic antigens 
on the surface of giRBCs would explain the observed low antibody 
reactivity.
Interestingly, a recent study demonstrated that surface recogni-
tion by naturally acquired antibodies was only present on erythro-
cytes infected with immature forms (I to III) of NF54 and a genetic 
strain with a Pf2004 background. In this study, no measurable 
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reactivity with the surface of giRBC infected with mature stage V 
gametocytes was observed.80 The authors emphasized that their 
contrasting findings could be due to the more stringent conditions 
in obtaining the different developmental gametocyte forms, with 
which RBC integrity and the activation of mature gametocytes into 
gametes were controlled for by counterstaining with antibodies 
specific to proteins on the gametocyte (not giRBC) surface. The au-
thors used a transgenic parasite line and flow cytometry to demon-
strate reactivity of the Malawian immune sera to antigens on the 
surface of immature giRBC, that are mostly shared with asexual 
infected erythrocytes. Subsequently, they used three complemen-
tary approaches to identify the antigenic targets. First, they probed 
giRBC membranes (stage I to III) with Malawian immune plasma to 
identify differential protein bands between surface-intact and sur-
face-depleted samples using mass spectrometry. Additionally, they 
probed sera of mice immunized with the membranes used for mass 
spectrometry on a protein microarray consisting of gametocyte pro-
teins.81 Lastly, they used the same protein microarray to construct 
an immune profile for a selection of the plasma samples that showed 
a range of membrane reactivity as identified using flow cytometry. 
Combining data of these three approaches and an initial filtering 
resulted in an overlapping list of 30 proteins of which 26 are pre-
dicted to be exported. The vast majority of these hits were shared 
with asexual life stages. Responses to giRBC were associated with 
increased phagocytosis of erythrocytes infected with both asexuals 
and gametocytes. This suggests a possible mechanism of increased 
clearance of giRBC by antibody-mediated phagocytosis. This study 
provides evidence for the presence of antigens on the surface of 
erythrocytes infected with immature gametocytes that are targeted 
by functional naturally acquired responses.
The functional phenotype of giRBC immunity may be related to 
interference with gametocyte sequestration or clearance of devel-
oping gametocytes. Based on the P. berghei model it seems likely that 
a subset of merozoites directly translocate into the bone marrow, 
spleen, and possibly other areas of low vascular flow, but it is also 
possible that some degree of homing occurs by early gametocytes.72 
Inside the bone marrow, adhesion of giRBCs to mesenchymal cells is 
observed,71 indicating the presence of early giRBC surface antigens. 
For inhibition of sequestration, targeting the initial homing of these 
tissues is a plausible transmission blocking strategy. Alternatively, an-
tibodies may neutralize gametocytes that are developing in the bone 
marrow. Both interference with sequestration and neutralization of 
developing gametocytes would result in a reduced release of ma-
ture gametocytes into the circulation. As such, giRBC immunity may 
contribute to the variation that is observed among natural infections 
in the production of P. falciparum mature gametocytes (Figure 2A), 
although this association remains to be established. Despite remark-
able differences in gametocyte development between P. falciparum 
and P. vivax, it has been demonstrated that there are similarities in 
sexual stage gene expression dynamics,20 suggesting conservation 
of pathways involved in sexual development. Erythrocytes infected 
with P. vivax parasites lack knob structures, so it was thought that 
ligand-receptor mediated sequestration was not possible for this 
species. However, it has been shown in several in vitro studies that 
P. vivax-infected erythrocytes can adhere to a variety of cells includ-
ing lung and brain endothelial cells.82,83 Furthermore, it has been 
demonstrated in human84 and non-human primate20 biopsies that P. 
vivax gametocytes sequester in the parenchyma of the bone marrow. 
Whether the P. berghei model of invasion followed by gametocyte 
development in the extravascular niche72 also applies to P. vivax re-
mains to be seen. In contrast to P. falciparum, P. vivax-infected eryth-
rocytes are deformable throughout all stages.85 This suggests that 
homing and retention are not mediated by membrane flexibility, but 
via ligand-receptor interactions. Interestingly, P. vivax parasites lack 
a homologue of PfEMP1, although they express a group of variable 
proteins (VIR)86 that have been implicated in tissue adhesion.82,87 
So far there have been no reports of naturally acquired immune re-
sponses against these proteins that potentially inhibit sequestration. 
The tight association between total parasite density and gametocyte 
density in P. vivax (Figure 2B) may argue against an important role of 
giRBCs immunity in affecting gametocyte production among natu-
rally infected individuals.
2.2 | Immune responses influencing 
gametocyte tropism
Mature gametocytes are ingested during a mosquito blood meal 
from the sub-dermal capillaries. Convincing evidence that gameto-
cytes accumulate preferentially in capillary beds is lacking88; how-
ever, one hypothesis is that mature giRBC surface antigens bind 
these tissues specifically (“tropins”) or facilitate their release from 
sequestration or visceral circulation at times when mosquitoes are 
feeding (“circadins”).89
STEVORs, RIFINS, and SURFINs are all hypothetical mature 
giRBC surface antigens, but as yet none have been shown to me-
diate gametocyte tropism in the sub-dermal capillaries.89 Though 
there is limited consensus in prior studies,66-69 recent work indicates 
that there is a progressive loss of giRBC surface recognition by im-
mune sera during gametocyte maturation.80 The lack of antigens on 
the surface of erythrocytes infected with mature gametocytes is a 
plausible mechanism of immune evasion, and there is a hypothesis 
that the specific crescent shape of P. falciparum mature gametocytes 
may be sufficient to result in their disproportionate accumulate in 
the capillary beds.90 Obviously, this cannot be the case for P. vivax 
gametocytes that are transmitted efficiently despite their spherical 
morphology. At present, there is therefore no evidence for the exis-
tence of “tropins” or “circadins” or associated immune responses that 
could affect gametocyte densities in the skin.
2.3 | Cellular immunity affecting circulating 
gametocytes
Although to a limited extent, anti-malaria cellular and innate im-
munity might play a role in reducing malaria transmission to 
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mosquitoes. It is well-established that merozoites and erythro-
cytes infected with asexual parasites are phagocytosed by mono-
cytes and neutrophils.91-94 The internalization of non-opsonized 
infected erythrocytes by monocytes and culture-derived mac-
rophages is mediated by interactions of CD36 and the parasite li-
gand PfEMP1.93 There is evidence that erythrocytes infected with 
stage I and stage IIa P. falciparum gametocytes are phagocytosed in 
a similar way.95 Phagocytosis of giRBCs later than stage II has not 
been demonstrated.95,96
The role of cellular immune mechanisms in the clearance of cir-
culating gametocytes is contentious. As erythrocytes lack major 
histocompatibility complex molecules, direct targeting of giRBCs 
by T lymphocytes is not possible. However, CD4 + T cells clearly 
respond to gametocyte antigens97-99 and appear capable of induc-
ing long lasting gametocytocidal immunity in rodent models.100 
Serum factors from splenectomized macaques (infected with P. cy-
nomolgi) taken at the point of infection “crisis” or paroxysm can kill 
gametocytes, and this appears to be mediated by inflammatory cy-
tokines including tumor necrosis factor-α (TNF-α) which stimulates 
leukocytes to produce toxic nitric oxides.101,102 In semi-immune P. 
vivax-infected humans, cytokine concentrations were insufficient 
to induce killing factors during paroxysm,103 and it is unclear how 
this may differ in non-immune humans. Interestingly, gametocyte 
killing factors appear non-specific to species or parasite stage; that 
is, the supernatant from peripheral blood mononuclear cells stim-
ulated with P. vivax schizont extract was able to kill P. falciparum 
gametocytes, and vice versa.102 T cell responses seem similarly 
non-specific to parasite stage.104 These data present an exciting 
avenue for whole parasite vaccine development,105 but it remains 
unclear whether infection crisis in humans leads to meaningful lev-
els of gametocyte death.
3  | IMMUNE RESPONSES AGAINST 
INTR A-ERY THROCY TIC GAMETOCY TES 
AND E XOERY THROCY TIC GAMETES
In contrast to the sparse and partially conflicting evidence for 
immune responses against intact giRBCs that may reduce circu-
lating gametocyte density, there is a large and cohesive body of 
data demonstrating that humoral responses to intra-erythrocytic 
gametocyte proteins can inhibit parasite development inside mos-
quitoes.44,81,106-122 The antigens responsible are not present on the 
erythrocyte surface but are expressed on the intra-erythrocytic 
gametocyte during their maturation in humans. Key gametocyte 
surface antigens shared by gametes are involved in processes nec-
essary for colonization of the mosquito midgut: egress from the 
RBC; male gamete exflagellation and exflagellation center forma-
tion; fertilization and ookinete invasion of the gut epithelium. As 
gametocytes die in the human host they are cleared by the spleen 
and the immune system is exposed to these antigens that are 
shared by the human and mosquito parasite stages. The resulting 
antibodies circulate in humans, but their functional consequence 
only becomes apparent in the mosquito, where they can inter-
fere with parasites in the mosquito midgut and cause inhibition or 
total arrest of the mosquito infection. Though the effect is likely 
to be transitory and quantitatively less profound compared to 
transmission inhibition, there is also some evidence that immune 
factors may lead to enhancement of gamete infectivity in certain 
conditions.123
The proof of principle for the existence of transmission reduc-
ing (TR) antibody responses comes from experiments in which birds 
were immunized with whole inactivated gametocytes or gametes in 
the 1950’s and 1970’s.42-44,106,124 Evidence for naturally acquired TR 
immunity acting to prevent mosquito stage parasite development 
comes from cross-sectional studies using mosquito feeding assays. 
Mendis et al109 showed that Sri Lankan individuals with acute P. vivax 
infections produced gamete specific antibodies, and that antibod-
ies from these patients inhibited transmission in direct membrane 
feeding assays (DMFA). Shortly after, Graves et al showed that 
similar mechanisms prevented P. falciparum gamete viability using 
the standard membrane feeding assay (SMFA), in which the effect 
of sera from patients in Papua New Guinea was tested on cultured 
gametocytes.108 These experiments demonstrated that the domi-
nant immune mediator of gametocyte infectivity appears to be the 
humoral immune response. Antibodies directed to surface antigens 
on the gamete surface may prevent fertilization via direct lysis of 
gametes by activation of the complement system,125,126 opsoniza-
tion resulting in immune cell-mediated lysis127 or agglutination of 
gametes.128,129
Parasite antigens that can be targeted by antibodies to inhibit 
transmission can be divided into two broad classes; prefertiliza-
tion and the postfertilization antigens. Prefertilization antigens 
are expressed during gametocyte development and contribute to 
the viability of mosquito stage gametes, zygotes and/or ookinetes. 
Antibodies to prefertilization antigens are naturally acquired in the 
human host only because the majority of gametocytes die in circu-
lation, releasing their intra-erythrocytic proteins. Postfertilization 
antigens are expressed solely in the mosquito vector; though tran-
scription may occur in circulating gametocytes, the resulting mRNA 
is held in translational repression until the gametocytes activate in 
the mosquito midgut.130 Consequently, humans do not acquire hu-
moral responses to these antigens. This second group of antigens is 
beyond the scope of this review, since no naturally acquired humoral 
responses are observed to these antigens.
The most studied prefertilization antigens are P48/45 and P230, 
which belong to the 6-cysteine protein family131 and play crucial 
roles in fertilization.132,133 These proteins were first identified as 
targets of transmission blocking monoclonal antibodies (mAbs) 
isolated from mice immunized with gametocyte/gamete prepa-
rations.48,107 The first evidence of naturally acquired antibody re-
sponses to these proteins was shown in sera from individuals from 
Papua New Guinea.108 P48/45 is attached to the surface of both fe-
male and male gametes via a glycophosphatidylinositol-anchor and 
forms a stable complex with P230.134-136 Male gametes of Pfs48/45 
and Pbs48/45 knock-out lines are unable to adhere and penetrate 
     |  197JONG et al.
female gametes, which results in a dramatic reduction of oocyst 
number.132 Although P48/45 is expressed on the surface of macrog-
ametes, its disruption in female gametes does not seem to affect 
their fertility. Replacing the endogenous Pb48/45 by its vivax ortho-
logue seemed to reduce oocyst development, but did not abolish it, 
indicating that there is probably functional conservation of P48/45 
in these two parasite strains since fertilization was not affected.137 
In P. falciparum gametocytes, Pfs230 is present on the gametocyte 
surface, and a 50 kDa fragment is proteolytically cleaved from the 
surface-bound protein after the parasite’s emergence from the 
RBC in the mosquito gut.138,139 Transgenic P. falciparum Pfs48/45 
knock-outs (KO) produce Pfs230, but it is not retained on the ga-
metocyte surface, indicating that Pfs48/45 mediates Pfs230 reten-
tion.133 Male gametes lacking Pfs230 are still able to undergo host 
cell egress and exflagellate but are unable to bind uninfected RBCs 
to form exflagellation centers. The importance of this protein in fer-
tilization is reflected by the significantly reduced oocyst numbers of 
the Pfs230 KO parasites.133
In alignment with their exposure on the surface of gametes and 
importance in gamete fertility, studies have shown that the presence 
and titer of naturally acquired antibody responses to Pfs48/45 and 
Pfs230 are statistically associated with serum transmission reducing 
activity (TRA).108,112,113,118,120,140 Though the TRA of mAbs against 
Pfs48/45 and Pfs230 was demonstrated decades ago,47,48,107 it 
was only recently shown that naturally acquired antibodies against 
Pfs48/45 and Pfs230 are functionally involved in natural TRA.81 
Antibodies against Pfs48/45 and Pfs230 were separately purified 
from six individuals whose antibodies (total IgG) showed high TRA in 
the SMFA. The purified antigen-specific IgGs were reconstituted to 
the original serum volume and tested in the SMFA. The α-Pfs48/45 
antibodies of one individual blocked transmission independently, 
whereas α-Pfs230 antibodies from another donor reduced trans-
mission significantly. Concentration of antibodies resulted in higher 
TRA for several donors. This was the first direct evidence of the re-
ducing potential of naturally acquired antibodies against Pfs48/45 
and Pfs230.
Besides P230, rodent and human parasites also encode a pa-
ralog P230p. This protein is only expressed by mature male gameto-
cytes.141 Disruption of the gene in P. berghei did not result in any 
defects throughout the life cycle, indicating that the protein is dis-
pensable.142 The p230p locus in P. berghei143-145 and P. knowlesi 146  
parasites has been commonly used as a neutral insertion cassette 
to generate transgenic parasites. On the other hand, P. falciparum 
mutants lacking Pf230p have a strongly reduced ability to bind 
erythrocytes to form exflagellation centers, similar to the ob-
served phenotype in Pfs230 KO parasites.147 Pf230p KO resulted 
in a dramatic reduction in oocyst density in mosquitoes, indicating 
an important role in fertilization. The misconception that Pfs230p 
is dispensable has resulted in the disregard of this protein as a tar-
get of TR immunity. To our knowledge mAbs targeting P230p in 
P. falciparum or P. vivax have neither been tested, nor have pro-
teins been produced for immunization studies with a view to TBV 
testing. Naturally acquired Pfs230p antibody responses have been 
assessed in one study, which linked the TRA of serum antibodies 
from individuals living in malaria endemic areas with the same in-
dividual's antibody responses to 315 gametocyte enriched pro-
teins.81 Pfs230p was not the focus of this study, but the microarray 
data generated are publicly accessible (https ://doi.org/10.5061/
dryad.8bp05 ). The magnitude of α-Pfs230p responses was not sig-
nificantly different between individuals with evidence of blocking 
transmission in the SMFA and individuals whose antibodies had 
no notable transmission reduction activity. However, the pro-
portion of individuals deemed “sero-reactive” in a mixture model 
was borderline significantly higher in blockers (13.6%) than in 
non-blockers (3.9%) for one of the two Pfs230p peptides tested 
(PF3D7_0208900.e1s2, P = .054). It should be noted that this anal-
ysis was not adjusted for false discovery from multiple compari-
sons, and the overall prevalence of responses was low (13/276). 
Further serological studies with Pfs230p in its native conformation 
will be valuable.
Pfs47 is another member of the 6-cysteine protein family131 
and is a paralog of Pfs48/45. It is specifically expressed in female 
gametocytes and present on the surface of female gametes, zy-
gotes and ookinetes.148,149 The protein is known to protect the 
ookinete from the mosquito complement system by disrupting the 
c-Jun N-terminal kinase pathway in A. gambiae.150 However, Pfs47’s 
role appears unessential as disruption of the gene does not result in 
a reduction in oocyst numbers in A. stephensi.148,151 Interestingly, in 
P. berghei the opposite has been demonstrated, with gene disrup-
tion resulting in a significant reduction of oocyst numbers.132,152 
Although Pb47 and Pfs47 are clear paralogs, there is only limited 
sequence conservation,153 which could explain the observed dif-
ferences in function. There has been contrasting evidence for 
the effect of mAbs against Pfs47. A study by van Schaijk et al148 
showed that transmission was not affected by any of the three 
different Pfs47 specific mAbs in the SMFA. However, recent data 
suggest that antibodies specific to the central region have the abil-
ity to reduce the number of ookinetes in the mosquito midgut and 
thereby reduce transmission to both A. gambiae and A. stephensi.154 
It remains unresolved whether Pfs47 has an essential role in either 
fertilization or ookinete protection. The magnitude and prevalence 
of naturally acquired antibodies to Pfs47 appear nearly identical in 
individuals with antibodies that block transmission in the SMFA and 
those without such antibodies.81
The observed differences in phenotype between P. berghei 
and P. falciparum after disruption of P230p and P47 suggest that 
there are functional differences in these proteins between these 
two Plasmodium spp. There are no data available with respect 
to the function of these proteins in P. vivax, and it remains un-
known whether they have an essential role in mosquito stage 
development.
The male-specific sterility gene (HAP2) was first identified in 
Arabidopsis thaliana,155 and HAP2 homologues were later identified 
in higher plants and protists, including P. berghei.156 In P. berghei 
HAP2 is expressed in gametocytes and is present on the surface of 
intra-erythrocytic gametocytes and microgametes. Disruption of 
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the gene results in reduced transmission by blocking gamete fer-
tilization.157 Using membrane dyes this report demonstrated that 
HAP2 is not involved in adhesion of gametes but plays a role in mem-
brane fusion during zygote formation. Serum from rodents immu-
nized with recombinant PbHAP2158 or PfHAP2159 inhibited oocyst 
development in the SMFA. Naturally acquired antibodies against the 
recombinant PfHAP2 were identified in sera from Malian adults159; 
however, it remains unclear if these functionally contribute to TRA 
in the field. No significant differences in PfHAP2-specific antibody 
magnitude or prevalence were observed between SMFA blockers 
and non-blockers in microarray analyses.81 However, it has been re-
cently demonstrated that sera from mice immunized with peptides 
targeting the fusion loop of PfHAP2 inhibit the transmission of P. 
falciparum gametocytes sourced from naturally infected donors.160 
These data make HAP2 an interesting antigen for more extensive 
study. To our knowledge there are currently no data testing HAP2 
function in P. vivax, though it seems likely that the function is con-
served in P. vivax based on the observed functional conservation of 
HAP2 throughout species.156
Antibody-mediated transmission reduction has been observed in 
the absence of Pfs48/45 and Pfs230 antibodies in serum,41,108,110,114 
and after active depletion of these antibodies from purified total IgG 
fractions.81 These observations have led to the hypothesis that anti-
body responses to other sexual stage pre-fertilisation surface-asso-
ciated proteins may contribute to naturally acquired TRA. In a recent 
microarray analysis of antibody profiles against gametocytes and 
TRA, antibody responses to 13 novel proteins were associated with 
TRA and displayed features that suggest surface expression. This in-
cludes Pf11-1 and PfGEST, which have both been implicated in the 
process of gamete egress from the erythrocyte.161-163 Monoclonal 
antibodies against Pf11-1 can reduce transmission possibly by inter-
fering with egress.162 PbGEST KO gametes show a clear defect in 
host cell egress163; however, there are no data on the P. falciparum 
orthologue. Future work should include the evaluation of these an-
tigens in rodent immunization studies to determine their potential 
to induce functional antibody responses. The remainder of the TRA 
associated antibody specificities in this analysis included largely con-
served proteins with an unknown function, so it remains to be seen if 
these have the potential to induce functional transmission blocking 
immunity.
Though antibodies targeting gametocytes has been the focus 
of epidemiological and vaccine focused research, other human 
immune factors are ingested by mosquitoes when they feed and 
co-circulate with parasites as they activate and develop in the mos-
quito gut. Human phagocytes are present in the predigested blood 
meal and gametes (after RBC egress) are potentially vulnerable to 
direct phagocytosis. It has been shown in vitro that extracellular 
gametes can be phagocytosed and that the addition of immune 
serum leads to an increase in phagocytosis.94 However, these pro-
cesses were inefficient in the environment of the mosquito midgut, 
probably due to the reduced temperature (26°C rather than 37°C). 
The role of human cellular immunity on mosquito stage parasites is 
likely to be limited.
4  | MODUL ATION OF TR ANSMISSION BY 
ANTI- GAMETOCY TE IMMUNE RESPONSES
4.1 | Read-outs and methods of assessment
Immune modulation of malaria transmission can be assessed directly 
using mosquito feeding assays,108,123 which can determine both the 
direct transmission potential of naturally infected hosts and the ef-
fect of host immune factors. The SMFA is the most controlled of 
these assays, in which plasma, serum or their purified components 
are added to a blood source containing cultured gametocytes.164 
Multiple SMFA feeds can be performed in parallel with the same in-
fective material, and all experiments are performed with a relevant 
control (eg the same infective material with plasma from non-ma-
laria endemic areas) allowing results to be combined and compared 
reliably between experiments. Transgenic parasites can be used to 
increase the scalability of the SMFA for population cross sectional 
screening, using luminescence as the assay read-out rather than dis-
section and oocyst counting.165 Alternatively, the DMFA allows the 
impact of immune factors to be assessed on locally circulating para-
site strains with more natural gametocyte characteristics (ie density, 
sex ratio, maturity). In its most basic form, the DMFA involves feed-
ing colony adapted mosquitoes with blood collected from naturally 
infected individuals to determine their transmission potential; as in 
the SMFA, the traditional read-out is the number of midgut oocysts 
or salivary gland sporozoites. To assess immune modulation, the 
plasma component of the blood sample (ie its autologous plasma) can 
be replaced with naive plasma, revealing the transmission potential 
of gametocytes in the absence of immune factors from the host. In 
this “serum-replacement” version of the assay (so called because an-
ticoagulants were not used when the assay was developed109) trans-
mission modulation due to the autologous plasma is determined by 
comparison to a feed where autologous plasma is removed and then 
replaced as a control for the methodological disturbance.166
The read-out of the SMFA and serum-replacement DMFA is 
generally reported as percent TRA. This is the percent inhibition of 
oocyst density (or sometimes prevalence) in test mosquitoes relative 
to the experimental control. For example, if mosquitoes that have 
fed on a blood meal containing test plasma results in a mean oocyst 
load of ten, and control mosquitoes have a oocyst load of 100, the 
percentage TRA would 90%. Transmission inhibition by immune fac-
tors is referred to as either transmission reducing (TR) immunity or 
transmission blocking (TB) immunity. Specifically, “blocking” should 
refer only to the total annulment of mosquito infection. Transmission 
enhancing (TE) immunity is less commonly reported than TR immu-
nity, and though random variation of mosquito infection rate around 
the baseline (control) is likely to be the cause of many observations 
of low level TE, there is substantial evidence for immune mediated 
enhancement of immunity.167 TE would be reported as a negative 
TRA, or a relative infectivity >100%. As with all biological systems, 
the results of feeding assays require confirmation; replicable TRA 
of ≥90% in the SMFA is viewed as high level reduction (equivalent 
to blocking in natural infections).168 The aim of TBV development 
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is to induce TB immunity, which will reduce the number of infected 
mosquitoes feeding on a vaccinee. TR and TE immunity are a contin-
uum (thus transmission modulation) while TB immunity is likely to be 
uncommon in nature, so we use the former terms.
4.2 | Plasmodium falciparum transmission 
modulating immunity
In experiments with sera from Papua New Guineans performed by 
Graves et al, serum TRA in SMFA experiments varied from −124% 
TRA (TE immunity) to 99.4% (TR immunity). TE immunity was appar-
ent in 10/41 sera (5/33 tested in duplicate).108 Subsequent studies 
have shown that TR immunity against P. falciparum develops rapidly 
after malaria exposure119 and is short lived.120,122 Cross sectional 
analyses show wide variations in the frequency and intensity of P. 
falciparum TR immunity,110,114,121 which is likely related to differ-
ences in sampling strategy and transmission intensity. Van der Kolk 
et al121 performed a rigorous assessment of transmission modulation 
in 642 sera from Cameroonian, Indonesian, and Tanzanian P. falci-
parum gametocyte carriers. SMFA showed that TR immunity was 
present in 48% of sera, while TE immunity was present in 7%. The 
reproducibility of these results was variable, but significant numbers 
retained their TE and TR activity in repeat feeds. For P. falciparum, 
studies with serum-replacement DMFA generally show increases in 
mosquito infection rates between 14% and 66% in the absence of 
host immune factors,114,116,169,170 corroborating the results of indi-
vidual studies that TR immunity is more common and has a greater 
effect size than TE immunity.
There is evidence that TR immunity is associated with the pres-
ence or titer of antibodies against mature P. falciparum gametocyte 
antigens.81,108,110-122,171-173 A synthesis of data from six studies 
which measured antibody-mediated TRA in the SMFA and measured 
α-Pfs48/45 and α-Pfs230 responses by enzyme-linked immunosor-
bent assay (ELISA)115,116,118-121 showed that there was a significantly 
increased likelihood of strong TRA (≥90%) for individuals seroposi-
tive for either antigen (combined odds ratio [OR] = 3.72 [1.96-7.15, 
P < .0001]).41 Despite the general consensus, several individual stud-
ies showed no association between α-Pfs230 and/or α-Pfs48/45 
and TR immunity.108,110,114,121 TR immunity has been observed in 
the absence of Pfs48/45 or Pfs230 antibodies, and vice versa.108,113-
115,120,121 These somewhat inconsistent findings suggest that TRA 
due to α-Pfs48/45 and α-Pfs230 antibodies is incomplete in most 
individuals, may be synergistic, and that responses to unknown ga-
metocyte surface proteins may also affect transmission. With an 
agent based model combining DMFA, antibody, and parasite density 
data, Ouédraogo et al recently demonstrated that antibodies against 
Pfs48/45 and Pfs230 were associated with up to 44% reduction 
in the proportion of infected mosquitoes and up to 70% reduction 
in oocyst density, among individuals with and without observable 
gametocytemia in Burkina Faso.171 Stone et al81 used plasma from 
numerous cross-sectional studies32,35,116,174-179 to assess anti-
body-mediated transmission modulation. As in previous studies, 
antibody-mediated TRA (quantified in SMFA) was statistically asso-
ciated with the presence of Pfs48/45 and Pfs230 antibodies (com-
bined OR 5.90 [95% CI: 2.1-16.7], P = .001). TR immunity correlated 
with antibodies against these en others antigens (including α-Pf11-1 
and α-PfGEST) were also associated with reduced infectivity in field 
based DMFA. P. falciparum gametocyte immune responses may 
therefore contribute to the substantial variation in mosquito infec-
tivity from natural gametocyte donors (Figure 2C,D).
4.3 | Plasmodium vivax transmission 
modulating immunity
In 1987, Mendis et al showed that naturally acquired antibody-
mediated immune responses to the sexual stages of P. vivax (con-
firmed using immunofluorescence) were able to block P. vivax 
gametocyte transmission in the DMFA.109 In this study, two-thirds 
of serum samples from acutely infected individuals in Sri Lanka 
(n = 40) mediated mid to high level reduction of autologous para-
site transmission, while three samples showed oocyst intensities 
in the presence of the test sera “considerably greater than in con-
trols”. In a subsequent study, the authors showed that the effects 
of this immunity were short-lived; reductions were associated with 
an interval of <4 months between a first and second infection.180 
Also, testing individuals with acute P. vivax infection, Carter and 
Mendis reported complete suppression of mosquito infection by 
22% of sera from Sri Lankans (n = 196), and enhancement of infec-
tivity in 12% of sera.181 A technically similar study by Ramsey et al 
showed that Mexican individuals with secondary P. vivax infections 
either completely blocked transmission or showed varying levels of 
reduction (n = 41). Individuals with primary infections produced a 
similar proportion of enhancing and reducing effects in the serum-
replacement DMFA (n = 63).182 TR immunity has been substanti-
ated by numerous other studies183,184 and is often accompanied by 
observations of enhancement.
Few studies assessed the presence of antigen-specific P. vivax 
sexual stage antibodies,185,186 and to our knowledge, none have 
associated specific antibody responses with TR immunity. This 
is likely due to difficulties expressing the proteins in significant 
quantities in correct conformation, and because the focus of sex-
ual stage protein production efforts has been on P. falciparum. 
Various studies however have assessed P. vivax gamete recogni-
tion using immunofluorescence assays; Mendis109 showed that 
there is a negative correlation between TRA and anti-gamete 
antibody titer, while Ranakawa180 showed this correlation only 
when mosquitoes were fed directly on patient blood, but not on 
the same blood source through a membrane feeder. A compara-
tive study of P. vivax-infected (n = 105) and uninfected individu-
als (n = 44) from Colombia also examined antibody titer and TRA 
using serum-replacement DMFAs. Among infected individuals, 
44.6% had 50%-89% TRA and 35.2% had ≥90% TRA. The correla-
tion between anti-gamete antibody titre and TRA was clear in ex-
posed, currently uninfected, individuals; individuals with low titres 
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tended to enhance transmission, and individuals with higher titres 
either had no effect or blocked transmission.184
4.4 | Evidence for transmission enhancing immunity
We recently reviewed the evidence for immune enhancement of 
Plasmodium transmission.167 In longitudinal assessments of P. cyn-
omolgi infection in macaques, anti-gamete antibody titer was shown 
to increase steadily from baseline, the peak level coinciding with a 
period of serum TR immunity.187,188 When the antibody concentra-
tion was lower (in the early phase of the infection, and after the peak 
during convalescence) TE immunity was observed, before eventu-
ally both antibody titer and relative infectivity returned to baseline. 
These findings mirrored observations that gametocytes appeared 
most infectious to mosquitoes at the very start of a blood stage in-
fection.189,190 A key study by Peiris et al showed that dilution of P. 
vivax anti-gamete antibodies in P. vivax-infected human blood led 
to enhanced oocyst infection in mosquitoes compared to controls; 
highly dilute immune serum and mAbs (which caused significant TRA 
at higher concentrations) promoted infection in experiments where 
gametocyte density was insufficient to cause infection without ad-
ditional factors.123 In the aforementioned study of P. vivax exposed 
individuals from Colombia, sera with varying levels of TRA were ti-
trated to study the effect of dilution on transmission modulation.184 
Dilution of sera with low TRA showed enhancement (−200%) when 
diluted, while dilution of sera with no TRA did not have the same ef-
fect, indicating a possible role for low levels of blocking antibodies 
in TE.
These studies collectively promote the hypothesis that ingestion 
of low sexual stage antibody titers may lead to enhanced mosquito 
stage infection. The work of Peiris et al123 shows that for P. vivax, 
enhancing antibodies have the same specificity as reducing antibod-
ies. Carter and Mendis suggested that antibody-mediated TE is the 
result of both low antibody titers and low inherent gametocyte in-
fectivity (ie low gametocyte densities).181 This was apparent in the 
time-course studies of P. cynomolgi,187 and stands in contrast to TR 
immunity that appears to follow intensive, recent gametocyte ex-
posure. The exact mechanisms of enhancement are unknown, but it 
may be that at low concentration, transmission reducing antibodies 
targeting shared surface antigens of both male and female gametes, 
though unable to neutralize the gametes or promote opsonization, 
may promote fertilization.123 In P. falciparum, the evidence for en-
hancement is less clear. Although multiple studies show low level 
immune-mediated enhancement for P. falciparum,108,113,121,164,172 
Ponnudurai et al164 reported minimal enhancement due to Pfs48/45 
and Pfs25 mAbs at low titer, and concluded that the phenomenon 
was due to experimental variation. Recent studies add weight to the 
enhancement hypothesis for P. falciparum; mAbs against the central 
peptides of the D2 region of Pfs47 (present on the gametocyte, gam-
ete, zygote and ookinete surface) blocked transmission to mosqui-
toes, while mAbs against proteins at the regions N-terminus gave 
rise to twice the number of midgut oocysts.154 The existence and 
relevance of TE presents an important knowledge gap in our under-
standing of how anti-gametocyte immunity influences transmission 
dynamics.
5  | MAL ARIA TR ANSMISSION BLOCKING 
VACCINE DE VELOPMENT
5.1 | The conserved nature of gametocyte antigens
The conservation of a protein across parasite isolates and species 
is an indicator for its specialization and functional preservation. 
Antigenic variation of P. falciparum RBC surface antigens results 
from the constant re-organization and variable expression of var 
genes.191 This gene family encodes the PfEMP1 surface protein 
that mediates immune evasion and sequestration. Although the 
var genes family is the most intensively studied, the genetic vari-
ation in non-var genes is increasingly appreciated. This is largely 
due to recent sequencing efforts and the availability of sequence 
data in open access databases (PlasmoDB,192 PlasmoView193 and 
Pf3k194). A common observation is that gametocyte-specific genes 
show higher sequence conservation than asexual blood stage-ex-
pressed genes.
Assuming positive selection for variant genes is part of an 
“arms race” between the human host and the parasite, there are 
several reasons why gametocyte proteins might be more con-
served than blood stage proteins. The human host immune re-
sponse will be targeted more towards the asexual blood stages as 
they vastly outnumber gametocytes during acute infection; <5% 
of microscopically detectable parasites are gametocytes in most 
endemic settings.195 However, this proportion appears to change 
with host age and immunity, transmission intensity, and duration 
of infection.30 Furthermore, asexual parasites actively remodel 
the RBC surface protein structure, while mature gametocytes 
do so to a lesser extent. This difference has implications for the 
antigenic targets of immunity because cytoplasmic, mitochon-
drial and nuclear proteins are more conserved than exported or 
apicoplast- and membrane-targeted proteins.196 Recently, the 
duality between internal and, potentially, secreted proteins was 
confirmed for immature gametocytes. It was shown that even a 
subset of surface-associated early gametocyte proteins had very 
little sequence variation indicating limited selection by host im-
munity.80 The limited genetic variation in gametocyte-specific 
genes is illustrated by challenges to discriminate the gametocytes 
from multiple clones. The sequences of Pfs48/45 and Pfs16 in lab-
adapted strains and isolates from Papua New Guinea showed few 
polymorphisms, while diversity in Pfs230 fragments allowed for 
some discrimination between samples.197 Genetic variation among 
P. falciparum TBV candidates and their orthologues in P. vivax is 
lower compared to key vaccine targets for the pre-erythrocytic or 
asexual blood stage (P. falciparum reviewed in,198 P. vivax reviewed 
in199) (Figure 3). The high sequence conservation of gameto-
cyte-specific genes make them attractive targets for vaccination, 
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since this increases the chance of being effective in a strain-tran-
scendent manner.
5.2 | Leading transmission blocking 
vaccine candidates
It is conceptually attractive to develop a vaccine that affects trans-
mission to mosquitoes by inducing immune responses that prevent 
sequestration, interfere with gametocyte maturation or target ma-
ture circulating gametocytes in the human host. Recent findings 
that antibodies against antigenic targets expressed on the giRBC 
surface are negatively associated with both asexual and gameto-
cyte load in Malawians80 provide a lead for further investigation 
that should demonstrate whether giRBCs are a viable target for 
immunization.
By comparison, there is a much longer history of TBV develop-
ment targeting antigens present on the surface of intra-erythrocytic 
gametocytes and exoerythrocytic gametes. The rationale for the 
development of these TBVs comes from above-mentioned animal 
studies where transmission reducing immunity was induced by vac-
cination44,106 and paved the way for the identification of P48/45, 
P230 and P25 as important TBV candidates.48,107
The post-fertilisation antigen P25 is the most extensively studied 
TBV candidate to date with a variety of vaccine constructs evaluated 
in both pre-clinical studies and clinical trials (reviewed by Chaturvedi 
et al200 and Mueller et al201) (Figure 4A). P25 contains four EGF-like 
domains with 22 cysteines202,203 and is anchored on the surface of 
zygotes and ookinetes.48 The first in-human trials with full-length 
Pfs25 showed modest immunogenicity,204 stimulating efforts to de-
velop more potent vaccine products, such as fusion with and coupling 
to carrier proteins (Pfs25-EPA,205 Pfs25-IMX313,206 Pfs25-GPI207), 
expression on virus-like particles208 or combining Pfs25 with other 
adjuvants.209,210 Administration of virus-like particles comprising 
Pfs25 in healthy US adults was safe but TRA of the induced anti-
bodies was weak.211 Pfs25 conjugated to Pseudomonas aeruginosa 
ExoProtein A (EPA) has been tested in malaria naive US adults, and is 
the only Pfs25 construct tested in malaria-exposed individuals. Four 
doses were required to induce higher functional transmission reduc-
ing antibody responses in a subset of vaccinated Malian adults com-
pared to the control group and antibody levels waned rapidly.212,213 
The future of Pfs25 as a TB vaccine is uncertain given the limited 
efficacy and the availability of other candidates that may hold more 
promise, including Pfs48/45 and Pfs230.
The development of vaccines against P48/45 and P230 has been 
challenging due to their complex native conformation. Pfs48/45 is a 
F I G U R E  3   Reported variations in Plasmodium falciparum and P. vivax vaccine candidates. All plasmoDB (v44) listed variations in P. 
falciparum (A) and P. vivax (B) vaccine candidates normalized for gene length. Transmission blocking vaccine (TBV) candidates in P. falciparum 
and their orthologues in P. vivax are indicated with a red box and dotted box, respectively. The displayed TBV candidates for P. falciparum 
harbor an average non-synonymous SNP density of 11.98 SNPs per kb coding sequence, while the pre-erythrocytic and blood stage 
candidates have significantly more non-synonymous SNPs (95.54, P = .017, Welch's t test). For P. vivax, the orthologues of P. falciparum 
TBV candidates have an average of 24.34 non-synonymous SNPs/kb, significantly less than the targets of asexual stage vaccine candidates 
(76.01 non-synonymous SNPs/kb, P = .011, Welch's t test). A premature stop codon is introduced by a non-synonymous SNP and as a result 
the stability and function of transcripts and proteins can be altered
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51.6 kDa protein and contains three domains with up to six conserved 
cysteines in each domain131,134,214 (Figure 4B). The correct forma-
tion of disulphide bridges within each domain is essential for proper 
protein folding, which is necessary for eliciting functional transmis-
sion blocking antibody responses.215 Production of correctly folded 
full-length Pfs48/45 with sufficient yield has had highly variable 
success rates in different heterologous expression systems includ-
ing baculovirus-insect cells,134 E. coli,216 Vaccinia virus,217 yeast,218 
Nicotiana benthamiana,219,220 green algae221 and Drosophila mela-
nogaster S2 cells.222 It has been demonstrated that the C-terminal 
fragment containing six cysteines (6C) (Epitope I) is the target of the 
most potent transmission blocking mAb (85RF45.1).223 Therefore, 
several truncated versions of Pfs48/45 were produced, both in E coli 
and Lactococcus lactis, including a two-domain fragment containing 
ten cysteines (10C)224-226 and the 6C fragment.227 Alternative ap-
proaches, to overcome problems with recombinant protein expres-
sion of Pfs48/45 include the use of DNA vaccines, showing promising 
results in non-human primates,228,229 and expression of Pfs48/45 
as a transgene in P. berghei parasites.145 After decades of limited 
success, TBV development of both full-length and a truncated ver-
sion of Pfs48/45 now show considerable progress222,225-227,230-233; 
both full-length Pfs48/45 and R0.6C (Pfs48/45-6C fused to the 
N-terminal region of the glutamate rich protein GLURP-R0) are being 
prepared for clinical trials in the near future.
The expression of Pfs230 has been even more challenging and 
has long lagged behind Pfs48/45. Pfs230 is over 300 kDa in size and 
contains 14 six cysteine motifs, which has hampered the expression 
of the full-length protein (Figure 4C). The first Pfs230-specific mAbs 
were generated by intraperitoneal injection of isolated P. falciparum 
macrogametes in mice.48 The isolated mAbs against Pfs230 lacked 
the ability to reduce transmission, a finding that nearly eliminated 
Pfs230 as a TBV candidate. It was subsequently demonstrated that 
a complement was required for the blocking activity of these mAbs 
to Pfs230,234,235 and that only mAbs of a complement fixing isotype 
blocked transmission.236
The production of six fragments of Pfs230 allowed the identifica-
tion of an N-terminal region of Pfs230 (C-region) that induces functional 
antibody response.237 A subsequent study aimed to further define the 
region by expression of smaller fragments of this C-region238; None of 
the truncated fragments was able to induce a functional antibody re-
sponse, while the anti-serum did recognize the native protein on gam-
etes. However, Tachibana et al more recently expressed the N-terminal 
C-region and several truncated versions thereof and demonstrated 
that antibodies induced by the whole C-region as well as the truncated 
(C2, C1 and C0) fragments were able to reduce transmission, even in 
the absence of complement.239 They emphasized that the minimal epi-
tope required to induce functional antibodies is the N-terminal pro-do-
main which does not contain cysteines.
F I G U R E  4   Native protein structure of Pfs25 (A), Pfs48/45 (B) and Pfs230 (C). (A) Schematic representation of the four EGF-like domains 
of Pfs25 with 22 cysteines with, underneath, the full-length vaccine construct used in preclinical and clinical studies. (B) Domain structure of 
Pfs48/45 with cysteines forming disulphide bridges (dotted lines) based on homology to other 6-cys domain proteins. Underneath, several 
vaccine constructs are presented that have been tested in preclinical studies. (C) Schematic of Pfs230 with 14 cysteine motifs (CM). The 
processing site is the location where the protein is cleaved after gamete emergence from the red blood cell. Underneath, vaccine constructs 
that have been tested in preclinical studies; Pfs230D1M has been tested in clinical studies (ClinicalTrial.gov NCT02334462 and ClinicalTrial.
gov NCT02942277). SP: Signal peptide; GPI: Glycosylphosphatidylinositol anchor
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Similar to Pfs48/45, many different expression systems have 
been used to overcome difficulties of expressing native epitopes 
of Pfs230. These include E. coli,237,238,240,241 a wheat germ cell-
free system,239 Nicotiana benthamiana,242 the baculovirus-insect 
cell system243,244 and DNA vaccination.245 Importantly, all Pfs230 
constructs that have been expressed in the recent years are based 
on the results of the first study demonstrating that region C is the 
only part that elicits functional antibodies.237 Recently, a systematic 
approach by Tachibana et al aiming to express 27 different protein 
fragments confirmed that the first cysteine motif is the main region 
for the induction of functional antibodies. Nevertheless, it cannot be 
excluded that other regions of Pfs230 are also targets of functional 
antibodies.
Currently, the most advanced Pfs230 construct in the clin-
ical pipeline is the Pfs230D1M construct expressed in yeast. This 
construct comprises amino acids 542 to 736 and has been conju-
gated to EPA.246 Sera of rabbits immunized with Pfs230D1M-EPA 
in Alhydrogel® were able to block transmission of cultured P. fal-
ciparum NF54 and two Thai patient isolates in the SMFA. Safety 
studies have been performed in US and Malian adults with this con-
struct formulated in Alhydrogel® (ClinicalTrial.gov NCT02334462) 
and AS01 (ClinicalTrial.gov NCT02942277). The results of these 
trials have to date not been reported. Recruitment is ongoing for a 
phase 2 trial using the Pfs230D1M-EPA/AS01 vaccine. In this trial, 
groups of healthy Malian children of decreasing age will be recruited 
(ClinicalTrial.Gov NCTO03917654).
While clinical trials are ongoing, more potent Pfs230-based 
formulations are being developed, including the conjugation of 
Pfs230D1M to the outer membrane protein complex which induces 
higher TRA responses in mice than Pfs230D1M-EPA.247
Plasmodium vivax TBV research has moved along the same path 
as that of P. falciparum, although the inability to culture P. vivax-in-
fected RBC in vitro (and thus gametocytes) has limited vaccine dis-
covery and evaluation.
The best characterized P. vivax TBV candidate to date is 
Pvs25.203 Early studies demonstrated that Pvs25 has a superior 
ability to induce potent transmission blocking antibodies compared 
to another ookinete surface protein Pvs28.248,249 Phase I clinical 
trials in healthy US adults using full-length Pvs25 expressed in 
Saccharomyces cerevisiae (Pvs25H)250 formulated in Alhydrogel® 
resulted in only modest induction of transmission blocking anti-
bodies.251 Preclinical adjuvant optimization studies demonstrated 
potent induction with Pvs25H formulated in Montanide,252-254 
but a phase I clinical trial was terminated due to unexpected high 
reactogenicity related to the adjuvant.204 This stimulated efforts 
to develop different vaccine antigen formulations with higher 
potency and lower undesirable reactivity, such as viral delivery 
systems255,256 or fusion to carrier molecules.257-259 It remains to 
be investigated whether these formulations are safe and improve 
Pvs25 immunogenicity in humans.
Full-length Pvs48/45 has been recombinantly expressed in 
E. coli with intact native epitopes as demonstrated by the reac-
tivity of antibodies in sera from Colombian individuals.185 Potent 
antibodies were induced in immunization studies using mice and 
monkeys as demonstrated by complete transmission blocking ac-
tivity in DMFAs using three natural isolates. Similar to Pfs48/45, 
Pvs48/45 recombinant protein expression has been challenging; 
Tachibana et al260 used DNA immunizations to overcome problems 
with protein folding. They immunized rodents with both full-length 
Pvs48/45 and the C-terminal cysteine rich domain equivalent to 
Pfs48/45 6C. Antibodies against full-length Pvs48/45 showed 
superior reactivity against protein lysates and reduced oocyst 
numbers. Whether antibodies against Pvs48/45 6C were able to 
reduce oocyst numbers has not been tested. Pvs47, orthologue 
of Pvs45/45, has also been tested in this study and antibodies in-
duced after DNA immunization were also able to reduce oocyst 
number. Using a similar approach, rodent immunizations with a 
fragment of Pvs230 based on the Pfs230C region (excluding the 
pro-domain) also demonstrated the induction of functional anti-
body responses.261 Interestingly, the reduction of oocyst numbers 
in the DMFA was not dependent on the addition of complement. 
These preliminary data indicate a potential for these pre-fertiliza-
tion antigens as TBV, but more extensive studies will be required 
to confirm feasibility.
Several TBV candidates (eg Pfs25,204,211-213 Pfs230 (Clinicaltrials.
gov NCT02334462 and NCT029442277) and Pvs25204,251) have 
been tested in clinical studies in the last two decades and Pfs48/45 
based vaccine constructs are currently being prepared for clinical 
testing. In addition, transmission blocking mAbs are increasingly 
being considered to reduce transmission in exceptional circum-
stances and support vaccine development.
6  | TR ANSMISSION BLOCKING 
MONOCLONAL ANTIBODIES
The importance of naturally acquired immunity in malaria was 
demonstrated in the 1960s by the passive transfer of polyclonal 
antibodies from adults to infected children, reducing parasitemia 
and alleviating (severe) clinical disease.262 It is increasingly recog-
nized that the B-cell repertoire of individuals who have been ex-
posed to and are protected against an infectious disease can be a 
rich source of highly potent mAbs. For human use, mAbs should 
be potent, target conserved epitopes and preferably be of human 
origin.
The first human mAbs against a sexual stage antigen were de-
rived from transgenic mice, ie mice expressing human immunoglob-
ulins, that were immunized with Pfs25. Characterization of these 
mAbs revealed sites associated with transmission blocking activity 
but also demonstrated that these mAbs have low potency.263 More 
recently, anti-Pfs25 mAbs were isolated from a human volunteer 
who was immunized with Pfs25. These mAbs target three different 
epitopes, two of which had been identified in the transgenic mice 
study. Interestingly, one of these human mAbs is the most potent 
anti-Pfs25 mAb described to date.264 A large panel of (potent) ro-
dent mAbs against other sexual stage targets is available and could 
204  |     JONG et al.
be of interest for therapeutic use upon humanization.265 Many of 
these mAbs were isolated after immunizations described above that 
contributed to the identification of P230 and P48/45 and showed 
high potency in the SMFA48,107,234,235 (Table 1).
Monoclonal antibody 63F2A2.2a is the most potent Pfs230 mAb 
to date. The most potent Pfs48/45 mAbs described to date target 
epitope I on the C-terminal 6-Cys domain.215,223 mAb 85RF45.1 
achieves >80% TRA at 1-5 μg/mL223,266,267 and is currently being 
developed for clinical testing. The variable sequence of the heavy 
and light chains was used to identify the closest human germline 
homologues and design a humanized antibody, TB31F, that had a 
similar affinity and potency as the parental mAb.267 Furthermore, 
crystal structures of both 85RF45.1 and TB31F with the C-terminal 
6-Cys domain revealed that the antibodies target a highly con-
served site on Pfs48/45.222,267 This suggests that TB31F will be 
effective against most P. falciparum strains, a finding that can be 
confirmed using DMFA with genetically diverse strains in field set-
tings. Interestingly, TB31F appears more stable than 85RF45.1, with 
higher aggregation and melting temperatures,267 highlighting one of 
many possibilities to engineer antibodies to introduce desired char-
acteristics.268 Although transmission reducing mAbs against other 
sexual stage targets such as Pfs25,48,263,269 Pf11-1,162 Pfs47154 have 
been identified, mAbs against Pfs230 and Pfs48/45 appear to be the 
most potent and may therefore be prioritized (Table 1). Rodent mAbs 
with TRA against P. vivax have been described. Crystallization of one 
of these in complex with Pvs25 revealed its binding site; however, 
the potency of this mAb has not been established.270 Monoclonal 
antibodies against P. vivax target unknown antigens and/or have 
very limited information on potency.123,183,271,272 Better character-
ization of these mAbs and identification of novel human mAbs will 
thus be required before considering clinical development of mAbs 
that target P. vivax transmission.
Isolation and characterization of human mAbs can also guide 
vaccine design, an approach that has been pioneered in the quest 
for a broadly neutralizing HIV vaccine.273 Only recently have re-
searchers started isolating human mAbs against malaria antigens. 
Two independent groups isolated B-cells from volunteers who were 
immunized with sporozoites and identified potent mAbs against 
Circumsporozoite Surface Protein (CSP) that are unique in binding 
both the NANP repeat as well as the junctional epitope.274,275 Not 
only are these good candidates for therapeutic antibodies, they also 
provide valuable information for vaccine design. Strikingly, the CSP 
targeting vaccine RTS,S (Mosquirix) lacks the junctional epitope. It is 
tempting to speculate whether including this epitope may increase 
vaccine efficacy.274-276 Another example of how mAbs can inform 
vaccine design comes from the structural studies of 85RF45.1 in 
complex with Pfs48/45 that describe epitope I.222,267 Since antibod-
ies against the epitope I are very potent, vaccine design should aim 
to direct antibody responses against this conserved epitope. This 
could for instance be achieved by either reducing immunogenicity 
of other regions on Pfs48/45 through amino acid mutations and gly-
cosylation or coupling of the antigen to virus-like particles in such a 
way that epitope I is well presented to cross-link B-cell receptors.
It is anticipated that many human mAbs against sexual stage 
targets will become available in the near future, either from indi-
viduals who are naturally exposed to gametocytes and exhibit high 
levels of TRA41,80 or from individuals taking part in ongoing clinical 
trials with Pfs230 (ClinicalTrial.gov NCT02334462, NCT02942277, 
NCTO03917654) or forthcoming trials with Pfs48/45. These devel-
opments will plausibly support the development of next generation 
vaccines and may potentially warrant further clinical development of 
mAbs for passive immunization.
7  | E VALUATION OF MAL ARIA 
TR ANSMISSION BLOCKING VACCINES
7.1 | Preclinical testing
TBVs and mAbs are recognized as tools with great promise for malaria 
elimination initiatives. As a consequence of the increased interest in 
elimination, the pipeline of candidate TBVs and mAbs with trans-
mission blocking properties has expanded considerably in recent 
years,178,206,232,233,257,277-280 not only in terms of antigens but also in 
terms of adjuvant formulations and delivery platforms. While TBVs 
are most likely to be used in combination with vaccines targeting 
other stages,281 guidelines of the US Food and Drug Administration 
stipulate that vaccine components require efficacy assessments as 
stand-alone products. There is currently no consensus on protocol 
design and endpoints of clinical trials with transmission blocking 
interventions. Given the complexity and expense of phase III field 
evaluations that are likely to involve cluster-randomized trials (CRT), 
it is, however, evident that robust pipelines for candidate prioritiza-
tion are needed.233 The early evaluation of TBV candidates currently 
depends on the SMFA where reductions in oocyst density or preva-
lence are used as indicators of vaccine potency.
Importantly, these in vitro assays are only available for P. fal-
ciparum and not for P. vivax for which parasite culture is currently 
not possible. In addition, SMFA typically relies on a single gameto-
cyte-producing P. falciparum parasite line at unnaturally high ga-
metocyte densities in combination with a single mosquito strain.282 
While the value of the SMFA for early TBV evaluation is beyond 
dispute, the assay has clear limitations when estimating the public 
health impact of TBVs. The only P. falciparum TBV with published 
results from a field study to date (Pfs25-EPA as described above) 
showed excellent results in in vitro assays but failed to induce sub-
stantial transmission blocking activity when serum of vaccinated 
volunteers from the United States was offered to mosquitoes with 
cultured gametocytes.213 The candidate proceeded to a clinical trial 
in Malian adults where it showed limited efficacy.212 This experience 
illustrates the challenges with early evaluation assays and the urgent 
need for a model to accelerate vaccine development and identify 
early failures of vaccine candidates.
One approach that allows preclinical samples, eg serum sam-
ples from rodents, in a real-life context is to add these antibody 
samples to giRBCs of naturally infected individuals in the DMFA. 
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These natural giRBC gametocyte donors can be infected with 
multiple gametocyte-producing clones,283,284 thus allowing the 
testing of antibodies induced in preclinical studies against genet-
ically diverse and complex gametocyte infections at natural ga-
metocyte densities using locally relevant mosquito populations.282 
This approach has been utilized to assess the efficacy of preclin-
ical and clinical samples for P. falciparum TBVs Pfs48/45, Pfs230 
and Pfs2581,178,285 and for preclinical samples for P. vivax TBVs 
Pvs48/45, Pvs230 and Pvs47 as described above.185,260,261 This 
ex vivo assessment of antibody efficacy may be used to support 
the interpretation of early immunogenicity trials and explore pos-
sible challenges with genetically diverse gametocytes and escape 
mutants.
8  | E ARLY CLINIC AL TESTING
An early evaluation model has recently been developed that may 
allow a direct assessment of vaccine efficacy against gametocytes 
that are induced in the vaccinated donor.
Controlled human malaria infection (CHMI) models provide pow-
erful tools for early evaluation of malaria vaccine candidates and 
have been used predominantly for pre-erythrocytic286-288 and blood 
stage289 vaccines. CHMI involve deliberate and controlled infection 
of malaria naive individuals with either sporozoites (by mosquito bite 
or intravenous injection of cryopreserved sporozoites) or parasitized 
erythrocytes (iRBCs).289-292 The appearance and timing of blood stage 
parasites can be used as an endpoint for CHMI testing pre-erythrocytic 
vaccines. Parasite multiplication rate can be used as an endpoint for 
blood stage286,289 vaccines. For TBV, CHMI-transmission models were 
recently developed using mosquito bite or iRBC inoculation with P. fal-
ciparum 3D7 parasites. Treatment of asexual parasites with a subcura-
tive dose of piperaquine monotherapy allows the production of viable 
mature gametocytes whose infectivity can be assessed by DMFA or 
direct skin feeding experiments. Both mosquito bite21 and iRBC inocu-
lation33 result in the production of male and female gametocytes in all 
volunteers. Gametocyte production is markedly higher following iRBC 
inoculation, for unknown reasons, and results in a higher likelihood of 
volunteers infecting mosquitoes by either DMFA or direct skin feeding. 
This model makes it possible to test the efficacy of highly efficacious 
TBVs for P. falciparum in small groups of 10-20 malaria naive volunteers 
per study arm, all infected with a single well-characterized parasite line 
(M. Alkema, I. J. Reuling, G. de Jong, K. Lanke, L. E. Coffeng, G-J. van 
Gemert, M. van de Vegte-Bolmer, Q. de Mast, R. van Crevel, K. Ivinson, 
C. F. Ockenhouse, J. S. McCarthy, R. Sauerwein, K. A. Collins, & T. 
Bousema, unpublished). A CHMI-transmission model with similar effi-
ciency in terms of induction of transmissible gametocytes has been de-
veloped for P. vivax (K. A. Collins, C. Y. T. Wang, M. Adams, H. Mitchell, 
G. J. Robinson, M. Rampton, S. Elliott, A. Odedra, D. Khoury, E. Ballard, 
T. B. Shelper, L. Lucantoni, V. M. Avery, S. Chalon, J. J. Moehrle, & J. S. 
McCarthy, unpublished). At present, CHMI-transmission studies have 
only been conducted in malaria naive volunteers, with the advance of 
TA B L E  1   Selected transmission blocking monoclonal antibodies
Target Name Target epitope Source Isotype Potency in SMFA
Pfs230 63F2A2.2a236 Unknown Mouse IgG2a 80% at 1 μg/mL, 100% at 4 μg/mL
P5E2-2F7-2B4234 Unknown Mouse IgG2a 72% at 10 μg/mL, 97% at 30 μg/mL
Pfs48/45 85RF45.5223 Epitope V Rat IgG2a 79% at 25 μg/mL, 98% at 50 μg/mL,
32F348,223 Epitope I Mouse IgG2b 61% at 12.5 μg/mL, 99% at 25 μg/mL
85RF45.1223,267 Epitope I Rat IgG1 IC80 = 1-2 μg/mL
TB31F267 Epitope I Humanised rat 
antibody
IgG1 IC80 = 0.5-1 μg/mL
Pfs25 4B7263,269 Site 1a/b, EGF3 Mouse  IC80 = 29 μg/mL
32F8148,311 LDTSNPVKT peptide on EGF3 Mouse IgG1 >80% at 10 μg/mL
AB1245263 Site 2, EGF1-4 Transgenic 
mouse
Generated 
as IgG1
IC80 = 263 μg/mL
AB1269263 Site 1a/b, EGF3 Transgenic 
mouse
Generated 
as IgG1
IC80 = 63 μg/mL
2530264 Site 3, mainly EGF2 Human  IC80 = 65 μg/mL
2544264 Site 1, EGF1/3/4 Human  IC80 = 16 μg/mL
Pf11-1 
(Pfs2400)
mAb1A1162 Nonamer repeat [PEE(L/V)
VEEV(I/V)]2
Mouse IgG1 70% & 80% at 93 μg/mL, 58% at 
44 μg/mL and 57% at 9 μg/mL
Pfs47 IB2154 Central region of domain 2 Mouse  66%, 70%, 84% & 88% at 200 μg/mL 
(4 feeds)
BM2154 Central region of domain 2 Mouse  74% & 94% at 200 μg/mL (2 feeds)
Note: For each target the most potent and human(ized) monoclonal antibodies (mAbs) are given. Note that information about potency is limited for 
many mAbs since these have often been tested at few, unknown or unspecified concentrations. All mAbs against Pfs230 are complement dependent, 
unlike mAbs against other targets.235,236
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CHMI studies in naturally exposed populations,293-295 it is only a mat-
ter of time until CHMI-transmission studies will also be conducted in 
endemic settings.
Conventional phase II trials in adult volunteers in endemic set-
tings may complement the clinical development pipeline for TBVs. 
In addition to immunogenicity and activity of serum samples of 
vacinnees in the SMFA, such studies can examine the transmissi-
bility of possible naturally acquired infections by DMFA or direct 
skin feeding.212 While incident infections in these studies, unlike 
CHMI-trans, are unpredictable and transmission endpoints may be 
underpowered unless sufficiently high gametocyte densities (eg >5 
gametocytes/μL31,33 are observed in a considerable fraction of study 
participants, they allow preliminary efficacy assessments against 
local parasite strains.
8.1 | Public health endpoint for TBVs
Definitive evidence on the public health endpoints of TBVs will require 
larger studies that are complex due to the intended outcome of vac-
cination that aims to reduce incident infections by reducing the re-
productive number (R0) of malaria and overall exposure to infective 
mosquitoes.296 As such, TBV confers a delayed individual benefit297 
that is achieved by reducing the number of mosquitoes that become 
infected when biting on vaccinated individuals296 and thereby pro-
gressively reducing the force of infection over multiple transmission 
cycles.298 The classic approach to phase III clinical trials with TBV, 
supported by regulatory agencies in consultation with the malaria re-
search community, is to conduct CRT where clusters (eg villages) are 
randomized to receive either TBV vaccination or no TBV vaccination 
(control arm).297 A cohort of participants in each cluster may be fol-
lowed for incident infections by molecular or conventional diagnos-
tics as definitive evidence for a reduction in the force of infection.299 
Infectivity of vaccinated and unvaccinated individuals to mosquitoes 
and Plasmodium sporozoite rates in field-caught mosquitoes are 
among the obvious secondary endpoints, and should provide insight 
into the mechanism of actions of TBV. As surrogate endpoints, it has 
been debated whether these outcome measures would allow for ac-
celerated approval,297 thereby allowing registration and postponing 
(but not annulling) the requirement to demonstrate the public health 
benefits of TBV until after vaccine implementation. No consensus has 
been reached in this discussion. The expectation that the largest ef-
fect size of TBV will be observed in low endemic settings (eg EIR < 8 in-
fectious bites/year300) or an incidence of infection below 0.2/person/
year301 and the large heterogeneity in malaria transmission intensity 
between and within clusters, implies that cluster-randomized trials will 
need to be large, involve many clusters and will be costly.
9  | CONCLUDING REMARKS
Early malaria research was dominated by investigations of the 
asexual blood stage that is the cause of clinical disease and 
mortality. Following the release of the first global malaria elimina-
tion framework in 2007,302,303 attention has shifted to include hu-
man-to- mosquito transmission as an important research interest. 
These efforts have improved our understanding of gametocyte bi-
ology as well as the epidemiology and infectivity of gametocytes. 
P. falciparum has been the primary focus of investigations to date, 
and our understanding of P. vivax gametocyte biology is limited. 
Several independent studies reported the presence of gameto-
cyte antigens on the P. falciparum giRBC membrane surface. While 
data are in part conflicting77-80 giRBC immunity may contribute 
to the large variation in gametocyte production observed in nat-
ural infections. Whether P. vivax giRBC immunity exists remains 
unknown.
While the existence of TRA is beyond dispute, and several key 
antigens are firmly established, the importance of TRA in determin-
ing natural transmission dynamics remains to be quantified.81,171 
This is particularly true for P. vivax where very few studies have ex-
amined the occurrence of gametocyte immunity and TRA in endemic 
populations or whether the kinetics of TRA differs with respect to 
mosquito-derived infection versus relapsing infection.
Compared to TRA, the potential importance of TE for the 
transmissibility of natural infections is very poorly understood. 
Understanding the dynamics of TRA and TE following natural ex-
posure and following vaccination may be particularly important for 
malaria elimination initiatives. Some evidence suggests that malaria 
transmission efficiency may increase as the burden of malaria de-
creases304; it is conceivable that waning gametocyte immunity may 
play a relevant role in this. Future research should quantify the ac-
quisition and waning of TRA in relation to malaria exposure, prove 
or disprove the existence of TE and unravel the associated immune 
profiles that may include other targets than the well-established 
Pfs48/45 and Pfs230.41,81,108,110,114
TBVs may play important roles in the malaria endgame, pre-
venting secondary infections from the remaining pockets of 
transmission, preventing malaria outbreaks and protecting other 
interventions from escape mutants.281 The discovery of giRBC 
immunity opens new avenues for TBV development. Great prog-
ress has also been achieved with conventional TBVs. Pfs25 has 
been the first vaccine to be tested in naturally exposed individ-
uals,212 providing invaluable insights for future field trials, and 
great progress has been achieved with TBVs targeting prefertil-
ization antigens. Several prefertilization TBV candidates are cur-
rently in, or approaching, clinical testing. Next generation TBVs 
may include novel immunogens or a combination of known an-
tigens. The future inclusion of multiple antigens may decrease 
the proportion of vaccinees who respond poorly,305 reduce the 
risk of escape mutant and potentially result in a synergistic ef-
fect.277,306-309 Currently, the most logical dual-antigen vaccine 
would include the top candidates Pfs48/45 and Pfs230 and pre-
liminary data of a chimeric protein showed potential synergy.310 
The increased pipeline of vaccine candidates and mAbs that 
aim to reduce transmission is promising and generates a sense 
of urgency to reach consensus on study designs to prioritize 
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candidates and accelerate testing and implementation processes 
of lead candidates. The expectation that cluster-randomized tri-
als for TBVs will be large and costly makes it unlikely that the 
international community can afford such trials for many TBV can-
didates. This is a strong argument to invest in early evaluation 
models, improve our understanding of transmission and continue 
to investigate naturally acquired and vaccine-induced immunity 
against gametocyte antigens.
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